<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/42/1396w–3a" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/42/1396w–3a/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/42/1396w–3a/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_1396w_3a"><akn:num>1396w–3a</akn:num><akn:heading>Requirements relating to qualified prescription drug monitoring programs and prescribing certain con</akn:heading><akn:content><akn:p>§ 1396w–3a. Requirements relating to qualified prescription drug monitoring programs and prescribing certain controlled substances(a) In generalSubject to subsection (d), beginning October 1, 2021, a State—(1) shall require each covered provider to check, in accordance with such timing, manner, and form as specified by the State, the prescription drug history of a covered individual being treated by the covered provider through a qualified prescription drug monitoring program described in subsection (b) before prescribing to such individual a controlled substance; and

(2) in the case that such a provider is not able to conduct such a check despite a good faith effort by such provider—(A) shall require the provider to document such good faith effort, including the reasons why the provider was not able to conduct the check; and

(B) may require the provider to submit, upon request, such documentation to the State.



(b) Qualified prescription drug monitoring program describedA qualified prescription drug monitoring program described in this subsection is, with respect to a State, a prescription drug monitoring program administered by the State that, at a minimum, satisfies each of the following criteria:(1) The program facilitates access by a covered provider to, at a minimum, the following information with respect to a covered individual, in as close to real-time as possible:(A) Information regarding the prescription drug history of a covered individual with respect to controlled substances.

(B) The number and type of controlled substances prescribed to and filled for the covered individual during at least the most recent 12-month period.

(C) The name, location, and contact information (or other identifying number selected by the State, such as a national provider identifier issued by the National Plan and Provider Enumeration System of the Centers for Medicare &amp; Medicaid Services) of each covered provider who prescribed a controlled substance to the covered indi</akn:p></akn:content><akn:subsection eId="subsec_1396w_3a_a"><akn:num>(a)</akn:num><akn:heading>In general</akn:heading><akn:content><akn:p>(a) In general Subject to subsection (d), beginning October 1, 2021, a State—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1396w_3a_b"><akn:num>(b)</akn:num><akn:heading>Qualified prescription drug monitoring program described</akn:heading><akn:content><akn:p>(b) Qualified prescription drug monitoring program described A qualified prescription drug monitoring program described in this subsection is, with respect to a State, a prescription drug monitoring program administered by the State that, at a minimum, satisfies each of the following criteria: A qualified prescription drug monitoring program described in this subsection, with respect to a State, may have in place, in accordance with applicable State and Federal law, a data-sharing agreement with the State Medicaid program that allows the medical director and pharmacy director of such program (and any designee of such a director who reports directly to such director) to access the information described in paragraph (1) in an electronic format. The State Medicaid program under this subchapter may facilitate reasonable and limited access, as determined by the State and ensuring documented beneficiary protections regarding the use of such data, to such qualified prescription drug monitorin</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1396w_3a_c"><akn:num>(c)</akn:num><akn:heading>Application of privacy rules clarification</akn:heading><akn:content><akn:p>(c) Application of privacy rules clarification The Secretary shall clarify privacy requirements, including requirements under the regulations promulgated pursuant to section 264(c) of the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. 1320d–2 note), related to the sharing of data under subsection (b) in the same manner as the Secretary is required under subparagraph (J) of section 1395w–104(c)(5) of this title to clarify privacy requirements related to the sharing of data described in such subparagraph.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1396w_3a_d"><akn:num>(d)</akn:num><akn:heading>Ensuring access</akn:heading><akn:content><akn:p>(d) Ensuring access In order to ensure reasonable access to health care, the Secretary shall waive the application of the requirement under subsection (a), with respect to a State, in the case of natural disasters and similar situations, and in the case of the provision of emergency services (as defined for purposes of section 1395w–104(c)(5)(D)(ii)(II) of this title).</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1396w_3a_e"><akn:num>(e)</akn:num><akn:heading>Reports</akn:heading><akn:content><akn:p>(e) Reports</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1396w_3a_f"><akn:num>(f)</akn:num><akn:heading>Increase to FMAP and Federal matching rates for certain expenditures relating to qualified prescription drug monitoring programs</akn:heading><akn:content><akn:p>(f) Increase to FMAP and Federal matching rates for certain expenditures relating to qualified prescription drug monitoring programs</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1396w_3a_g"><akn:num>(g)</akn:num><akn:heading>Rule of construction</akn:heading><akn:content><akn:p>(g) Rule of construction Nothing in this section prevents a State from requiring pharmacists to check the prescription drug history of covered individuals through a qualified prescription drug monitoring program before dispensing controlled substances to such individuals.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1396w_3a_h"><akn:num>(h)</akn:num><akn:heading>Definitions</akn:heading><akn:content><akn:p>(h) Definitions In this section:</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>